Ambicare Health

Ambicare Health is a spin-out company from NHS Tayside, SHIL and the University of St Andrews.

Founded in 2004, Ambicare has made substantial progress in the development and commercialisation of proprietary, wearable LED-based devices for treating a range of skin conditions and diseases. The company has developed two distinct, clinically proven product lines for the treatment of specific dermatological conditions: non-melanoma skin cancer and acne.

The patented platform technology allows the patient to wear the light delivery device in daily use, enhancing convenience to the user and delivering improved end results through consistency of light delivery to the skin.

Their acne product, Lustre Pure LightTM has obtained FDA clearance to be sold OTC in the US.

Find out more about Ambicare Health.

Aridhia

Aridhia was founded in 2007 as a spin-out company from SHIL.

AnalytiXagility, the company’s cloud-based data analysis platform, is a secure, self-service platform built to enhance the way researchers in biomedical research, precision medicine and healthcare environments access and analyse data.

AnalytiXagility brings the economic and adoption benefits of 3rd generation consumer technologies to research, accelerating data and analytical processes in a secure and reproducible way, and supporting trusted data sharing within a secure, audited and transparent environment.

Today, AnalytiXagility is used by ground-breaking research organisations around the world to enable the execution of collaborative research projects and business models including pre-competitive drug trials, multi-institutional data-driven precision medicine initiatives, and integrated healthcare programmes.

Find out more about Aridhia.

Aurum Biosciences

Aurum Biosciences Ltd is a 2015 spin-out company of SHIL, NHS Greater Glasgow and Clyde and the University of Glasgow.

A clinical stage biopharmaceutical company, Aurum is developing novel oxygen carriers and proprietary software for use with MRI, initially for Acute Ischaemic Stroke (AIS), as well as a pipeline of other products.

Headed by a team of experts in the field and working closely with NHS Greater Glasgow and Clyde and the University of Glasgow, Aurum is developing all of its products to address areas of high unmet medical need.

Find out more about Aurum Biosciences

CardioPrecision

CardioPrecision Ltd is an award-winning medical device company.

The company has developed an innovative and patented technology that allows clinicians to perform minimally invasive intervention through a short transverse incision to the neck. Key benefits include much less pain and faster recovery than current approaches. Secondary benefits may include reduced blood loss, lower rates of transfusion/infection and much shorter hospital stay. The technology aims to provide both improved clinical outcome for patients and economic savings for healthcare providers.

The company’s CoreVista® device has been successfully used in both surgical and transcatheter aortic valve replacement procedures.  Other cardiovascular applications are envisaged with similar benefits for patients and healthcare providers.

Clear Surgical

Clear Surgical was set up in 2013 as a spin-out from SHIL.

A medical device company, the team develop innovative solutions to surgical problems. Products include the only disposable, self-retaining illuminated retractor for improving the field of light in surgical cavities and the cannulated reduction forceps that act as a universal guidance system for use in treating fractures for orthopaedic patients.

Find out more about Clear Surgical.

Touch Bionics

Touch Bionics began as an idea from NHS Lothian and became the first SHIL spin-out in 2002.

Originally called Touch EMAS (Edinburgh Modular Arm System), in 2005 it was re-branded Touch Bionics to communicate the dynamism of the company’s products and the future focus on its prosthesis technology: bionics in medicine being the replacement or enhancement of organs or other body parts by mechanical means.

An initial SMART award from Scottish Enterprise started the company, and it has since received funding from existing and new investors including Archangel Informal Investments, TriCAP, Clydesdale Bank and the Scottish Co-investment Fund.

On 11 April 2016 Touch Bionics was acquired by Össur, a recognised "Technology Pioneer" and global leader in non-invasive orthopaedics that help people live a life without limitations, in a sale worth £27.5m.

Find out more about Touch Bionics.